Coronary/Structural Heart

Heartbeat Health Successfully Completes SOC 2® Type 2 Security Compliance Certification

Virtual-First Cardiology Company, Heartbeat Health, Achieves SOC 2® Security Control Compliance Certification, Reinforcing Its Commitment to Healthcare Data Security & Privacy. NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) — Heartbeat Health, a Virtual-First Cardiology company that leverages data, device connectivity, and clinicians to deliver on-demand cardiovascular services, announced today that […]

Jardiance® (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction

– The breakthrough approval expands the existing indication of Jardiance® to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe – European marketing authorization follows the U.S. Food and Drug Administration (FDA)’s approval received on 24 February 2022 […]

CIRCA SCIENTIFIC HAS RECEIVED FDA CLEARANCE FOR NEW ESOPHAGEAL TEMPERATURE PROBE THAT IS VISIBLE ON 3D CARDIAC MAPPING SYSTEMS

S-CATH™ M is the only rapid-response, high-density esophageal temperature probe that is visible on 3D cardiac mapping systems. ENGLEWOOD, Colo., March 3, 2022 /PRNewswire/ — CIRCA Scientific, Inc. announced today that its S-CATH™ M Esophageal Temperature Probe is now cleared for sale in the United States. The new S-CATH M Probe can be […]

The Argos Cardiac Output Monitor Interface is Declared Compatible with Philips IntelliBridge, Enabling Seamless Data Transfer to Hospital Electronic Medical Record (EMR) systems

VALHALLA, N.Y., March 2, 2022 /PRNewswire/ — Retia Medical today announced that it received a Declaration of Compatibility from Philips for its Argos Cardiac Output Monitor to interface with Philips IntelliBridge system on the IntelliVue patient monitoring systems. The Argos Monitor is now a compatible and “supported device” for Philips IntelliVue Patient […]

DispatchHealth and The American College of Cardiology Announce Innovative Collaboration Focused on In-Home Cardiovascular Care

DENVER and WASHINGTON, March 2, 2022 /PRNewswire/ — DispatchHealth, the nation’s first comprehensive in-home high acuity medical provider, today announced its collaboration with The American College of Cardiology (ACC), a nonprofit professional medical society, to enhance the lives of cardiovascular disease patients. The first of its kind, the collaboration between DispatchHealth and ACC is designed to […]

Cytokinetics Announces Cohort 4 of REDWOOD-HCM Is Open to Enrollment

Cohort 4 to Enroll Patients with Non-Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the opening of enrollment in Cohort 4 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), an ongoing Phase 2 clinical trial of aficamten, an investigational next-generation cardiac […]

Global Health Technology Company CardieX and Mobvoi Launch a Revolutionary Heart Health Monitoring Smartwatch for Consumers

The TicWatch GTH Pro features Arty® Heart Health technology, powered by ATCOR, a subsidiary of CardieX, to monitor arterial and heart health IRVINE, Calif. and SYDNEY, March 1, 2022 /PRNewswire/ — Mobvoi Inc., a leading artificial intelligence-wearable company backed by Google™ and Volkswagen, in partnership with global health tech company CardieX, today announces the launch of […]

Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial

– Adults hospitalized for acute heart failure were 36% more likely to experience a clinical benefit over 90 days if initiated on Jardiance after stabilization and before discharge compared with placebo – The benefit was consistent in adults with new or existing heart failure and in those with either preserved […]

BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada

SUNNYVALE, Calif., March 01, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has received a No Objection Letter from Health Canada, the country’s health services agency, allowing the CardiAMP® Heart Failure Trial to […]

Renovacor Announces Partnerships with the Dilated Cardiomyopathy Foundation, the Heart Failure Society of America and the American Association of Heart Failure Nurses to Help Increase Awareness of Genetic Heart Disorders

PHILADELPHIA–(BUSINESS WIRE)–Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced partnerships with the Dilated Cardiomyopathy (DCM) Foundation, the Heart Failure Society of America (HFSA) and the American Association of Heart […]